Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 2020

View Archived Issues

X chromosome is finished

Metabolic reprogramming promotes ADPKD cystogenesis

Phase III data presented for SCT-800 in severe hemophilia A patients

AZP-2006 studied in phase II for progressive supranuclear palsy

TIE2 IgG monoclonal agonistic antibody PMC-403 stabilizes vessels to enhance antitumor therapy

First-in-human study examines CAR-37 T cells in relapsed/refractory CD37+ hematologic malignancies

Novel engineered mouse model of GvHD

Discovery of novel anti-ILT2 monoclonal antibody, BND-22

Agios Pharmaceuticals presents Mat2A inhibitors

Newave Pharmaceutical divulges Bcl-2 inhibitors

CytoDyn presents safety data from phase II COVID-19 trial of leronlimab

FutureChem identifies FOLH1-binding radiopharmaceuticals

FORMA Therapeutics synthesizes USP9X inhibitors

Shanghai Dude Medical Science and Technology discovers TRK inhibitors

IMM-124E shows neutralizing activity against SARS-CoV-2

First patient dosed in phase II study of taletrectinib in NSCLC with ROS1 fusion

FDA places partial clinical hold on PRS-343

Researchers develop mouse model for imaging of Ca2+ changes in platelets

TNFR2 agonistic and antagonistic antibodies developed at BioInvent for treating solid tumors

FDA approves Qutenza for neuropathic pain associated with DPN of the feet

Phase III Measure Up 2 study of Rinvoq in atopic dermatitis meets primary and secondary endpoints

CTA cleared for phase I/IIa study of LUNAR-COV19 vaccine candidate

Bristol-Myers Squibb begins phase I/II study of BMS-986315 in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 18, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...